A Bioequivalence Study of Sunitinib Malate Capsules.
Status:
Completed
Trial end date:
2019-01-12
Target enrollment:
Participant gender:
Summary
A randomized, open, two-period, two-sequence crossover trial design used to assess the
pharmacokinetics and safety of Sunitinib Malate Capsules in healthy volunteers under fed
condition, and compare the bioequivalence of Sunitinib Malate Capsules produced by Pfizer and
Chia Tai Tianqing Pharmaceutical Group Co., Ltd, respectively.